Electric vehicle manufacturer Clear group CEO Peter Rawlinson said back on Tuesday because the corporate expects greater than double vehicle production to twenty,000 units this yr.

Lucid said Marc Winterhoff, Chief Operating Officer of the corporate, took over the interim CEO. Rawlinson will act as a “strategic technical advisor for the CEO and come from his earlier roles, the earlier roles”, ” The company said.

Winterhoff announced CNBC on Tuesday that it was Rawlinson's decision to resign from Friday, but he refused to work out additional details.

“It was Peters decision after 12 years, let's say day by day or day by day activities and the corporate by which it’s today … that it’s time to step aside and pass the staff” Berger in December 2023.

In an announcement Posted on Tuesday on LinkedInRawlinson said he decided that it was “finally the correct time” to launch the company's second product, a three-row SUV called the Gravity, “successful” after “successfully”. He did not explain the decision in the lengthy post.

Rawlinson's departure is unexpected. As one of the largest shareholders of the company, Rawlinson, who also acted as a Chief Technology Officer, routinely advertised his passion and his share in the car manufacturer. In July 2021, he took the public public through an reverse merger with a special employment company (Special Purpor Acquisition “(Spac).

“My mission and my commitment are steadfast. I did not sell a single damned share of this share, except what was necessary for tax purposes,” said Rawlinson throughout the company's call within the third quarter in November. “So my promise is to continue working tirelessly day and night to increase this long -term shareholder value.”

Lucid's board of directors initiated a search to discover a brand new CEO, the corporate said.

The CEO change and the production goal announced along with the automobile manufacturer's financial leads to the fourth quarter. For the period that ended on December 31, the corporate reported a net lack of net that’s on account of $ 636.9 million or a loss of twenty-two cents per share for sales of USD 234.5 million.

Analysts asked by LSEG expected a lack of 25 cents per share of the turnover of $ 214 million.

In the identical period of the previous yr, Lucid reported a net desire to be on account of $ 653.8 million or a lack of 29 cents per share, sales of $ 157.2 million.

The production goal for 2025, which was announced on Tuesday, is compared with the production of 9,029 vehicles and deliveries of 10,241 for 2024.

According to Winterhoff, the production of gravity SUV will regularly construct in the middle of the yr. He declined to invest what percentage of the production goal with 20,000 units would represent the vehicle.

Lucid's shares were 8% higher during trade on Tuesday.

At the tip of the market, the corporate's shares decreased by around 13% this yr, since they decreased more slowly than expected from all electrical vehicles and uncertainties for the support of the federal government for EVS as a part of the Trump management. The share decreased by around 28% last yr.

Lucid is basically supported by the general public investment fund Saudi -Arabia. His first product was the air limousine that began at the tip of 2021.

Shares of vaccine makers fell on Thursday as President-elect Donald Trump named Robert F. Kennedy Jr., a distinguished vaccine skeptic, to move the Department of Health and Human Services.

Shares fell in the ultimate hour of trading Reports Trump's expected election got here. ModernShares closed down greater than 5% on Thursday Novavax fell by greater than 7% and PfizerShares closed down greater than 2%.

Shares of BioNTechthe German drugmaker, which was co-developing a Covid vaccine with Pfizer, closed greater than 6% lower. British drug manufacturer GSKwhich makes flu shots and several other other vaccines, closed about 2% lower.

Shares of those firms fell further in prolonged trading as Trump confirmed his election in a post on his Truth Social platform.

Health policy experts say a second Trump term could allow Kennedy to sharpen his anti-vaccine rhetoric, which could deter more Americans from receiving Covid shots and routine vaccinations which have saved hundreds of thousands of lives and prevented debilitating diseases for a long time.

Pfizer, Moderna and Novavax are still recovering from falling Covid vaccination rates within the US which have dented their profits over the past two years.

Kennedy's track record as a vaccine skeptic is extensive. He has a protracted history of constructing misleading and false statements in regards to the safety of vaccines, corresponding to claiming that they’re linked to autism, despite quite a few decades-long studies refuting this link.

Kennedy is the founding father of the nonprofit Children's Health Defense, the country's most well-funded anti-vaccine organization.

Brazilian aircraft manufacturer Embraer is studying the market and recent technologies that would justify constructing a wholly recent jet, CEO Francisco Gomes Neto told CNBC.

A brand new plane could help the plane maker compete with much larger rivals Airbus and Airbus Boeingwhich delivers a whole bunch of jets annually, in comparison with Embraer's dozens of aircraft.

However, Gomes Neto noted that no decisions have been made yet.

“At this point we have no concrete plans for a tall, narrow body,” he said, adding that studies “need to be prepared” for brand new engine technologies, avionics and potential demand.

In the meantime, Gomes Neto said Embraer is concentrated on improving results and selling its regional aircraft, which received orders earlier this yr American Airlinesmanufacturing its E2 jet and “delivering what we promise our customers.”

Embraer said Friday that it delivered 16 business aircraft within the third quarter, up greater than 5% from a yr earlier. Including its defense and business aircraft, the corporate delivered 57 jets within the period, a 3rd greater than the previous yr.

The Federal Aviation Administration approved a freighter version of its passenger-to-freighter conversion E190 jet earlier this month, paving the way in which for business introduction.

“That’s perhaps the advantage we have: We have a great product.” [that’s] available,” said Gomes Neto.

Both Airbus and Boeing are having difficulty ramping up production and delivering aircraft on time in the wake of the pandemic. Boeing faces the additional challenges of a safety crisis and a machinists' strike.

Boeing once had plans to take control of Embraer's commercial aircraft business, but ended those talks in early 2020. Last month, Embraer said Boeing would pay $150 million for the failed plan.

Like its competitors, Embraer is facing supply chain strains due to the pandemic, and the company is taking a closer look at delivery capabilities.

Engines, hydraulic valves, cabin interiors and components for them are some of the areas where it is difficult to increase production from suppliers, said Gomes Neto. He added that he expects supply chain issues to likely ease in 2026.

French video game publisher Ubisoft is facing questions on its future as the corporate struggles with a lackluster games pipeline and pressure from investors to pursue a sale.

The company that produces the “Assassin's Creed” series announced in an updated forecast last week that it had postponed the discharge of the following title in the favored game series – called “Assassin's Creed Shadows” – by three months to February 14, 2025 has .

Ubisoft also lowered its forecast for the 2024-2025 financial 12 months and now expects net bookings to fall to around 1.95 billion euros. Ubisoft expects net booking revenue of 350 million to 370 million euros for the second fiscal quarter, down from the previously expected 500 million euros.

“The revised goals primarily reflect the decisions made for Assassin's Creed Shadows and the weaker start than expected for Star Wars Outlaws,” Ubisoft said.

This comes after the corporate's game “Star Wars Outlaws” – an action-adventure title based on the enduring sci-fi film series released this summer – posted disappointing sales and received a mixed response from gamers. Ubisoft said that lessons learned from the discharge of Star Wars Outlaws led it to provide more time to remodel Assassin's Creed Shadows.

The company also announced that it had scrapped its plans to release its recent Assassin's Creed game with a “Season Pass,” which was a paid add-on that may provide access to a bonus quest and extra downloadable content at launch offered.

Ubisoft added that it now plans to release Assassin's Creed Shadows on Valve Corporation's online game store Steam on launch day, ending its track record of exclusively distributing PC versions of its games through Epic Games' digital storefront.

“Given recent challenges, we recognize the need for greater efficiency while keeping players happy,” Ubisoft CEO Yves Guillemot said within the statement last week, adding that the corporate’s board is launching a review to further implement it to enhance.

Ubisoft shares have fallen to decade lows amid gloomy investor expectations for its triple-A games pipeline and financial outlook.

To further compound the corporate's woes, the corporate is facing a possible strike in France after the video game union there, STJV, called for 3 days of business motion from October 15 to 17 over the corporate's efforts to bring staff back to the office has three days per week.

Following the choice to delay the upcoming Assassin's Creed game, AJ Investments, an activist investor with lower than 1% stake in Ubisoft, said it was working with other shareholders in the corporate to influence the French company to go private -Equity corporations to sell or to the Chinese gaming giant Tencent.

Tencent owns around 10% of Ubisoft.

In an open letter last week, AJ Investments said it had won the support of 10% of Ubisoft shareholders for its pressure campaign, adding that it planned to work with proxy advisory firms to organize for the vote at the corporate's next annual general meeting to organize. CNBC couldn’t independently confirm this figure.

“We have spoken to industry experts as potential board members and executives to replace current management and achieve our strategic goals. We will propose our candidates in due course,” said AJ Investments.

AJ Investments said it is going to speak to Ubisoft management on Tuesday to debate its proposals. The company added that it might display in front of Ubisoft's headquarters in Montreuil, Paris, if vital.

Several banking analysts lowered their price targets on Ubisoft following news that the upcoming game was delayed, although many left their rankings unchanged.

Deutsche Bank, which downgraded the stock to “Hold” from “Buy,” said that Ubisoft's cut to its forecast was “larger than we expected” and that the postponement of Assassin's Creed Shadows “will require a significant portion of revenue into the next one.” Fiscal 12 months postponed”. .

Deutsche Bank's George Brown also said that he expected Assassin's Creed Shadows to perform worse than he initially expected, predicting sales of seven million units for the 12-month period after release. That's down from the previous forecast of 8 million.

Meanwhile, JPMorgan said in a press release last week that it now expects lower sales of Ubisoft's triple-A game releases and sees a slower release frequency going forward. JPMorgan maintained its “neutral” rating on Ubisoft shares, but lowered its price goal from 21 euros to 11 euros.

“Mid-sized developers continue to face pressure from development cost inflation, which is not accompanied by sufficient volume/monetization improvement to maintain attractive returns,” JPMorgan analysts Daniel Kerven and David W. Peat said within the note.

“UBI’s capital structure and lack of cash generation in recent years has resulted in UBI coming under increasing pressure to reduce capex/costs.”

Nevertheless, some analysts showed more understanding of Ubisoft's problems.

Analysts at Wedbush Securities suspected that the corporate was the victim of coordinated “trolling” by people attempting to lower average user rankings for the corporate's Star Wars Outlaws game on review sites.

“We believe Star Wars Outlaws was influenced by a coordinated effort aimed at trolling Ubisoft games specifically and Star Wars content in general,” Wedbush analysts Michael Pachter, Alicia Reese and Kade Bar wrote last week within the note.

“The game received an unusually high number of user reviews with a clearly negative bias (including a large percentage of “zero” reviews), despite having acceptable review scores from reputable review sites. “This is a case of a rare incel victory that led to Ubisoft having to record its numbers,” they added.

Analysts at Wedbush said that despite delays to the upcoming Assassin's Creed title, they expect the sport to sell 7 million units in its launch quarter and consider it “has the potential to become one of Ubisoft's best-sellers ever.”

Ubisoft's problems come because the broader video game space faces an industry-wide slump.

According to research firm Newzoo, the worldwide gaming market will grow just 2.1% year-on-year in 2024. That is in comparison with 0.5% growth in 2023but nowhere near the rapid growth rates observed throughout the Covid-19 pandemic years of 2020 and 2021.

James Lockyer, technology research analyst at British investment bank Peel Hunt, said a part of the issue for game publishers today is that gamers are devoting more time to older games than newer titles.

“In the post-Covid years, the number of games released per year has increased significantly,” Lockyer told CNBC via email. “As a result, consumers have had more choice in recent years.”

“However, greater choice and tighter budgets when it comes to cost of living have resulted in consumers’ money being spread more thinly, resulting in sales and ROI.” [return on investment] “One of these games often fell short of expectations,” he added.

LONDON – Danish biotech company Bavarian Nordic said on Friday that it had submitted data to the European Union's medicines regulator to expand using its Mpox vaccine in adolescents.

CEO Paul Chaplin told CNBC that the expanded eligibility for 12- to 17-year-olds is critical to contain the outbreak of the most recent virus variant group 1b, which particularly affects teenagers and young children.

Earlier on Wednesday, the World Health Organization declared an escalating MPOX outbreak in Africa a public health emergency after the primary case of the brand new variant outside the continent was confirmed in Sweden on Thursday.

“The latest data we have presented is really, really important because it will hopefully help expand the use of our vaccine in adolescents as well,” Chaplin told Squawk Box Europe.

“More than 70 percent of cases in Africa currently affect people under 18, so it is crucial that our vaccine can also be used in this younger age group,” he said.

Bavarian Nordic's Jynneos vaccine, also often called Imvanex, is currently only approved to be used in adults ages 18 and older. It can also be the one mpox vaccine approved by the U.S. Food and Drug Administration and the European Medicines Agency.

If the EMA approves the vaccine for teenagers, the corporate says this might pave the best way for approval for teenagers in Africa. The company can also be currently studying the effectiveness of the vaccine in children aged 2 and over. The results are expected next 12 months.

Following the WHO's declaration of a state of emergency, Bavarian Nordic's share price rose 17 percent on Thursday, as did other stocks within the healthcare sector, as demand for the vaccine was expected to extend. By midday on Friday, the share price in Copenhagen was up one other 17.5 percent.

Chaplin said the corporate has significant stockpiles of the vaccine and it’s “ready to ship” to countries in need, but he pointed to shortages in Africa which have thus far prevented distribution.

The vaccine is currently only approved within the Democratic Republic of Congo – the epicenter of the outbreak – and Nigeria. Chaplin said the corporate continues to work with authorities in affected neighboring countries to enable access to the vaccine.

“There is now an approval in the Democratic Republic of Congo and also in Nigeria. That now opens the door, both for governments to buy the vaccine and for Bavarian Nordic, as we have done, to donate doses and have those doses shipped and hopefully we can start vaccinating people very, very soon,” he said.

So far this 12 months, greater than 15,000 cases and not less than 537 deaths have been reported from the outbreak, in line with to the WHOIt follows an earlier outbreak of a distinct strain of Mpox in 2022, which was also declared a public health emergency.

The European Centre for Disease Prevention and Control warned on Friday of a high risk of infection for travellers to affected countries, however the WHO said it was not recommending border closures at the moment.

Chaplin said authorities were now higher in a position to tackle the outbreak because vaccine doses were already available, particularly in wealthy countries that had built up large stockpiles through the last outbreak. But he urged greater international cooperation to make sure vaccine doses reached those that needed them most.

“Bavarian Nordic is part of the solution, but we are not the only solution,” he said. “The international community needs to work with Bavarian Nordic and really find a way to distribute this vaccine and contain the outbreak.”

Novo Nordisk reported weaker-than-expected second-quarter net profit on Wednesday and revised down its operating profit forecast.

The pharmaceutical giant said its net profit for the three months to the top of June was 20.05 billion Danish kroner ($2.93 billion), compared with an overall forecast by LSEG of 20.9 billion Danish kroner.

EBIT (earnings before interest and taxes) amounted to DKK 25.93 billion within the second quarter, also below the LSEG forecast of DKK 26.86 billion.

Novo Nordisk also lowered its operating profit forecast for the complete 12 months 2024, Growth is now expected to be between 20 and 28 percent as an alternative of the previously expected range of twenty-two to 30 percent.

Novo Nordisk shares fell by almost 7 percent at one point, but were then capable of make up for his or her losses and were last trading at 9:40 a.m. London time, down 2.71 percent.

In the primary quarter of 2024, the Wegovy maker reported a 28% increase in net profit to DKK 25.4 billion year-on-year, barely increasing its forecasts for sales and operating profit growth.

Expectations for sales growth were raised again on Wednesday. The company now issued a forecast of twenty-two to twenty-eight percent at constant exchange rates for the complete 12 months 2024. Previously, the sales growth forecast for this era had been estimated at 19 to 27 percent.

Sales of the favored weight-loss drug Wegovy increased by 55% within the second quarter of 2024 in comparison with the identical period in 2023, reaching 11.66 billion crowns.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, said on Wednesday that the corporate expects “attractive growth” in the approaching months.

“We are very confident that we can scale and also serve patients and now achieve stronger growth for the second half of the year. So I say, worry less about what is happening specifically in [the second quarter]there have been some adjustments in discounts etc., look at our forecast and we believe there is very attractive growth ahead,” he told CNBC's “Street Signs Europe.”

Novo Nordisk faces increasing competition within the weight-loss space from each smaller corporations and pharmaceutical giants akin to Roche, which last month released promising results from early-stage testing of its own potential obesity drug.

Jørgensen said that while the initial test data may attract attention, it might not impact Novo Nordisk's business within the short term. Referring to Novo Nordisk's product pipeline, the CEO said he stays “very confident” that the corporate can “remain competitive in the long term.”

Novo Nordisk's Wegovy has also brought promising news in recent months. The drug was approved in China within the second quarter, making it available on the earth's second-largest economy. Elsewhere, British and European health authorities said they might back Wegovy since it could reduce the chance of great heart problems in chubby and obese adults.